{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Otolaryngologic+Disease&page=38",
    "query": {
      "condition": "Otolaryngologic Disease",
      "page": 38
    },
    "page_size": 10
  },
  "pagination": {
    "page": 38,
    "page_size": 10,
    "total_count": 2314,
    "total_pages": 232,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Otolaryngologic+Disease&page=39&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Otolaryngologic+Disease&page=37&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T00:23:03.889Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02318303",
      "title": "To Study GSP 301 in Patients With Seasonal Allergic Rhinitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Seasonal Allergic Rhinitis"
      ],
      "interventions": [
        {
          "name": "GSP 301-1 NS (QD)",
          "type": "DRUG"
        },
        {
          "name": "GSP 301-2 NS (BID)",
          "type": "DRUG"
        },
        {
          "name": "GSP 301 Placebo NS",
          "type": "DRUG"
        },
        {
          "name": "Olopatadine HCl-1 NS (QD)",
          "type": "DRUG"
        },
        {
          "name": "Olopatadine HCl-2 NS (BID)",
          "type": "DRUG"
        },
        {
          "name": "Mometasone Furoate-1 NS (QD)",
          "type": "DRUG"
        },
        {
          "name": "Mometasone Furoate-2 NS (BID)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Glenmark Pharmaceuticals Ltd. India",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 1111,
      "start_date": "2014-12",
      "completion_date": "2015-02",
      "has_results": true,
      "last_update_posted_date": "2020-10-20",
      "last_synced_at": "2026-10-16T00:23:03.889Z",
      "location_count": 10,
      "location_summary": "Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Kerrville",
          "state": "Texas"
        },
        {
          "city": "New Braunfels",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02318303"
    },
    {
      "nct_id": "NCT06323460",
      "title": "Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8",
        "Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8",
        "Oropharyngeal Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "External Beam Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2024-03-21",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-24",
      "last_synced_at": "2026-10-16T00:23:03.889Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06323460"
    },
    {
      "nct_id": "NCT01530659",
      "title": "Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Retinitis Pigmentosa",
        "Usher Syndrome Type 2",
        "Usher Syndrome Type 3"
      ],
      "interventions": [
        {
          "name": "NT-501",
          "type": "DRUG"
        },
        {
          "name": "Sham",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Neurotech Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 22,
      "start_date": "2012-01",
      "completion_date": "2019-07-01",
      "has_results": true,
      "last_update_posted_date": "2023-02-14",
      "last_synced_at": "2026-10-16T00:23:03.889Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01530659"
    },
    {
      "nct_id": "NCT04972162",
      "title": "Fitting Strategy Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hearing Loss, Sensorineural"
      ],
      "interventions": [
        {
          "name": "Web App Strategy Fitting",
          "type": "DEVICE"
        },
        {
          "name": "Standard-of-care Fitting",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "WSAUD A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2021-07-26",
      "completion_date": "2021-11-12",
      "has_results": true,
      "last_update_posted_date": "2025-09-30",
      "last_synced_at": "2026-10-16T00:23:03.889Z",
      "location_count": 1,
      "location_summary": "Vermillion, South Dakota",
      "locations": [
        {
          "city": "Vermillion",
          "state": "South Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04972162"
    },
    {
      "nct_id": "NCT05954273",
      "title": "Maxillary Sinus Membrane Perforation Incidence During Osseodensification",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Sinus Floor Augmentation",
        "Sinus Infection"
      ],
      "interventions": [
        {
          "name": "Osseodensification crestal sinsus graft",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Versah",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "21 Years to 90 Years"
      },
      "enrollment_count": 500,
      "start_date": "2023-04-03",
      "completion_date": "2023-08-28",
      "has_results": false,
      "last_update_posted_date": "2023-07-24",
      "last_synced_at": "2026-10-16T00:23:03.889Z",
      "location_count": 1,
      "location_summary": "Jackson, Michigan",
      "locations": [
        {
          "city": "Jackson",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05954273"
    },
    {
      "nct_id": "NCT03422341",
      "title": "Validation of the GenePOC Strep A, C/G Assay for Detecting Group A, C and G β-hemolytic Streptococcus From Throat Swabs.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pharyngitis, Infective"
      ],
      "interventions": [
        {
          "name": "Comparison between GenePOC CR and Reference Method",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Meridian Bioscience, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "25 Months and older"
      },
      "enrollment_count": 497,
      "start_date": "2018-02-14",
      "completion_date": "2018-07-11",
      "has_results": false,
      "last_update_posted_date": "2021-05-04",
      "last_synced_at": "2026-10-16T00:23:03.889Z",
      "location_count": 5,
      "location_summary": "Madera, California • Indianapolis, Indiana • Detroit, Michigan + 2 more",
      "locations": [
        {
          "city": "Madera",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03422341"
    },
    {
      "nct_id": "NCT03162224",
      "title": "Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer",
        "Human Papilloma Virus"
      ],
      "interventions": [
        {
          "name": "MEDI0457",
          "type": "DRUG"
        },
        {
          "name": "CELLECTRA®5P device",
          "type": "DEVICE"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 35,
      "start_date": "2017-06-26",
      "completion_date": "2021-03-19",
      "has_results": true,
      "last_update_posted_date": "2022-08-25",
      "last_synced_at": "2026-10-16T00:23:03.889Z",
      "location_count": 14,
      "location_summary": "San Francisco, California • Orlando, Florida • Atlanta, Georgia + 10 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03162224"
    },
    {
      "nct_id": "NCT00022373",
      "title": "Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Head and Neck Cancer",
        "Oral Complications of Radiation Therapy",
        "Radiation Toxicity"
      ],
      "interventions": [
        {
          "name": "iseganan HCl oral solution",
          "type": "DRUG"
        },
        {
          "name": "management of therapy complications",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2000-12",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-10-15",
      "last_synced_at": "2026-10-16T00:23:03.889Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00022373"
    },
    {
      "nct_id": "NCT02578641",
      "title": "A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Nasopharyngeal Carcinoma"
      ],
      "interventions": [
        {
          "name": "autologous EBV specific Cytotoxic T cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "combination IV gemcitabine and IV carboplatin (AUC2)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Tessa Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 330,
      "start_date": "2014-07",
      "completion_date": "2022-02-28",
      "has_results": true,
      "last_update_posted_date": "2023-06-28",
      "last_synced_at": "2026-10-16T00:23:03.889Z",
      "location_count": 7,
      "location_summary": "Duarte, California • Sacramento, California • San Francisco, California + 4 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02578641"
    },
    {
      "nct_id": "NCT06421766",
      "title": "Retrospective Study of Outcomes With 3 mm Implant for Percutaneous BAHS Procedures",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hearing Loss"
      ],
      "interventions": [
        {
          "name": "BAHS",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Oticon Medical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 234,
      "start_date": "2024-03-08",
      "completion_date": "2024-09-25",
      "has_results": false,
      "last_update_posted_date": "2025-07-31",
      "last_synced_at": "2026-10-16T00:23:03.889Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06421766"
    }
  ]
}